GlassScriptPhysician profile
Rena A Azar
NPI 1760537484
$22,816.52
in general payments reported to CMS, 2019-2025
31 companies · $649 in 2025
The $649 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $230 · 2021: $394 · 2022: $1,654 · 2023: $413 · 2024: $8,355 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $7,857 · Food and Beverage: $1,268 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $7,856.64 |
| Food and Beverage | $1,268.35 |
| Education | $290.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $9,971.87 | 2019 | |
| Medtronic, INC. | $9,432.16 | 2022-2025 | Interstim, Altaviva |
| Boston Scientific Corporation | $914.13 | 2019-2025 | Wavewriter Alpha Prime 16, Axonics, General - Female Sui |
| Astellas Pharma US INC | $751.69 | 2019-2025 | Veozah |
| Pfizer INC. | $251.55 | 2019-2025 | |
| Abbvie INC. | $220.27 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Sumitomo Pharma America, INC. | $187.40 | 2023-2025 | Myfembree, Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $157.95 | 2019-2024 | Trintellix |
| Myovant Sciences INC. | $117.10 | 2021-2022 | |
| Urovant Sciences INC | $90.23 | 2021-2022 | |
| Therapeuticsmd, INC. | $84.25 | 2019-2021 | |
| Eisai INC. | $81.16 | 2019-2021 | |
| Axonics, INC. | $59.99 | 2020-2022 | |
| Amag Pharmaceuticals, INC. | $49.13 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.17 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $46.20 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $45.06 | 2021 | |
| Allergan, INC. | $40.26 | 2020 | |
| Laborie Medical Technologies Corp. | $31.64 | 2024 | Urgent PC Neuromodulation System |
| Exact Sciences Corporation | $29.06 | 2023 | Cologuard Collection Kit |
| Exeltis, USA INC. | $25.97 | 2021-2022 | |
| Olympus America INC. | $21.12 | 2024 | Olympus |
| Tela Bio, INC. | $21.10 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Vertex Pharmaceuticals Incorporated | $19.96 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.66 | 2022 | |
| Caldera Medical, INC | $19.02 | 2021 | |
| Baxter Healthcare | $17.58 | 2023 | Adept |
| Mayne Pharma Commercial LLC | $17.14 | 2025 | |
| Axsome Therapeutics, INC. | $16.02 | 2023 | Auvelity |
| Currax Pharmaceuticals LLC | $15.83 | 2020 | |
| Avion Pharmaceuticals | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rena Azar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.